APA (7th ed.) Citation

Liu, Y., Zhao, X., Wang, X., & Zhou, Q. (2025). Adverse events of hepatic anti-fibrotic agents in phase 3 and above clinical trials. Frontiers in Pharmacology, 16, . https://doi.org/10.3389/fphar.2025.1534628

Chicago Style (17th ed.) Citation

Liu, Yuwei, Xu Zhao, Xinrui Wang, and Qiang Zhou. "Adverse Events of Hepatic Anti-fibrotic Agents in Phase 3 and Above Clinical Trials." Frontiers in Pharmacology 16 (2025). https://doi.org/10.3389/fphar.2025.1534628.

MLA (9th ed.) Citation

Liu, Yuwei, et al. "Adverse Events of Hepatic Anti-fibrotic Agents in Phase 3 and Above Clinical Trials." Frontiers in Pharmacology, vol. 16, 2025, https://doi.org/10.3389/fphar.2025.1534628.